Trials / Conditions / Multiple Endocrine Neoplasia Type 1

Multiple Endocrine Neoplasia Type 1

12 registered clinical trials studyying Multiple Endocrine Neoplasia Type 1 — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 D NCT06790251	F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore	—
Recruiting	Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients NCT06523582	Universidad Nacional Autonoma de Mexico	—
Recruiting	Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients NCT05037461	J.M. de Laat	N/A
Recruiting	Natural History Study of Parathyroid Disorders NCT04969926	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	—
Active Not Recruiting	Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors NCT03950609	M.D. Anderson Cancer Center	Phase 2
Withdrawn	Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine NCT02831179	Vanderbilt-Ingram Cancer Center	Phase 1
Terminated	68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors NCT03001349	M.D. Anderson Cancer Center	EARLY_Phase 1
Recruiting	Familial Investigations of Childhood Cancer Predisposition NCT03050268	St. Jude Children's Research Hospital	—
Unknown	EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors NCT05554744	Guangxi Medical University	N/A
Completed	Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With NCT02101918	National Cancer Institute (NCI)	Phase 2
Recruiting	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168	Sanford Health	—
Completed	Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer NCT00454363	National Cancer Institute (NCI)	Phase 2